감염증용 임상 검사실 분자진단 시장 : 용도별, 장소별, 국가별 전략과 동향, 예측 - 시장 분석 및 경영자용 가이드 포함(2026-2030년)

Report Overview:

Molecular diagnostics for infectious disease testing represent one of the most dynamic and strategically important segments of the clinical laboratory testing market. These diagnostic technologies detect nucleic acids associated with pathogens such as viruses, bacteria, fungi, and parasites, enabling rapid and highly accurate identification of infectious agents. Molecular diagnostic methods offer significant advantages over traditional microbiology approaches by providing improved sensitivity, specificity, and faster time to result, enabling clinicians to initiate appropriate treatment more quickly and reduce transmission of infectious diseases.

The global market for clinical laboratory molecular diagnostics for infectious disease testing is estimated to exceed approximately USD 12-18 billion annually, with projected compound annual growth rates in the range of approximately 6-10% over the next decade. Growth is supported by increasing awareness of infectious disease risks, expanding adoption of multiplex testing technologies, and continued development of new molecular diagnostic platforms.

Molecular diagnostic testing plays an essential role in clinical decision-making by enabling accurate pathogen identification and supporting appropriate therapeutic selection. Rapid detection of infectious organisms can improve patient outcomes, reduce unnecessary use of broad-spectrum antibiotics, and support infection control efforts within healthcare settings.

Technology Overview

Molecular diagnostic tests detect pathogen-specific nucleic acid sequences using amplification or sequencing technologies. Polymerase chain reaction (PCR) represents the most widely used molecular diagnostic method due to its high sensitivity and adaptability across a broad range of pathogens. Real-time PCR technologies allow rapid detection and quantification of pathogen DNA or RNA in clinical samples.

Isothermal amplification technologies such as loop-mediated isothermal amplification (LAMP) and transcription-mediated amplification (TMA) provide alternatives to PCR that enable rapid testing without complex thermal cycling equipment. These technologies are particularly valuable for decentralized and near-patient testing environments.

Next-generation sequencing (NGS) technologies are increasingly used for pathogen identification, epidemiological surveillance, and detection of antimicrobial resistance markers. Sequencing-based diagnostics enable unbiased detection of pathogens and identification of genetic mutations associated with drug resistance.

Multiplex molecular diagnostic panels enable simultaneous detection of multiple pathogens from a single patient sample. Syndromic testing panels are commonly used for respiratory infections, gastrointestinal infections, and bloodstream infections, providing clinicians with comprehensive diagnostic information.

Advances in automation and sample preparation technologies have improved workflow efficiency and reduced time to result.

Clinical Applications

Clinical laboratory molecular diagnostics are widely used in the detection and management of infectious diseases across multiple clinical settings. Respiratory infection testing represents one of the largest segments, including detection of pathogens such as influenza virus, respiratory syncytial virus (RSV), SARS-CoV-2, and other respiratory pathogens.

Sexually transmitted infection (STI) testing represents another important application area, including detection of pathogens such as Chlamydia trachomatis, Neisseria gonorrhoeae, human papillomavirus (HPV), and herpes simplex virus (HSV).

Gastrointestinal pathogen testing is used to detect bacterial, viral, and parasitic organisms associated with diarrheal disease and foodborne illness.

Bloodstream infection testing supports rapid identification of pathogens associated with sepsis, enabling timely therapeutic intervention.

Hospital-acquired infection testing supports infection control programs by identifying organisms such as methicillin-resistant Staphylococcus aureus (MRSA) and Clostridioides difficile.

Molecular diagnostics are also used for detection of antimicrobial resistance markers, supporting appropriate antibiotic selection and stewardship programs.

Public health laboratories use molecular diagnostics for surveillance of emerging infectious diseases and monitoring of pathogen evolution.

Market Drivers

Several factors are driving growth in the clinical laboratory molecular diagnostics for infectious disease market.

Increasing prevalence of infectious diseases continues to create demand for accurate diagnostic testing.

Growing awareness of antimicrobial resistance is increasing demand for rapid pathogen identification and resistance detection.

Expansion of multiplex syndromic testing panels is improving diagnostic efficiency and reducing time to treatment.

Advances in molecular biology technologies are enabling development of new diagnostic assays.

Increased investment in public health infrastructure is supporting expansion of molecular testing capacity.

Decentralization of diagnostic testing is expanding use of molecular technologies in point-of-care settings.

Integration of molecular diagnostics into clinical guidelines is supporting adoption by healthcare providers.

Global travel and population mobility increase risk of emerging infectious disease transmission.

Market Structure and Segmentation

The clinical laboratory molecular infectious disease diagnostics market can be segmented by technology, application, end user, and geographic region.

By technology, PCR-based testing represents the largest segment, followed by isothermal amplification technologies and sequencing-based diagnostics.

By application, respiratory infection testing represents one of the highest-volume segments, followed by sexually transmitted infections, gastrointestinal infections, bloodstream infections, and hospital-acquired infections.

End users include hospital laboratories, independent reference laboratories, public health laboratories, physician office laboratories, and decentralized testing environments.

North America represents the largest regional market due to established healthcare infrastructure and high adoption of molecular testing technologies.

Europe represents a significant market supported by well-developed laboratory systems.

Asia-Pacific markets are expanding due to increasing investment in healthcare infrastructure and diagnostic technologies.

Competitive Landscape

The molecular infectious disease diagnostics market includes multinational diagnostic companies, specialized molecular diagnostics developers, and emerging biotechnology firms.

Competition is driven by assay sensitivity, specificity, turnaround time, ease of use, and breadth of test menu.

Instrument placement strategies often involve long-term reagent supply agreements that generate recurring revenue streams.

Companies are increasingly developing integrated diagnostic platforms combining sample preparation, amplification, detection, and software analysis.

Digital connectivity and data management capabilities are becoming increasingly important competitive differentiators.

Strategic partnerships between diagnostic companies and public health organizations support development of new testing solutions.

Future Outlook

The clinical laboratory molecular diagnostics for infectious disease market is expected to continue expanding as healthcare systems emphasize rapid detection of infectious pathogens and improved antimicrobial stewardship.

Multiplex testing panels are expected to become increasingly widely adopted as clinicians seek comprehensive diagnostic information from single tests.

Sequencing technologies may play an expanding role in outbreak surveillance and antimicrobial resistance monitoring.

Point-of-care molecular diagnostic platforms may improve access to testing in decentralized healthcare settings.

Artificial intelligence tools are expected to improve interpretation of complex molecular diagnostic data.

Overall, molecular diagnostics represent a critical component of modern infectious disease management and public health preparedness. Continued advances in molecular biology technologies, automation, and data analytics are expected to support sustained market growth.

Table of Contents

1 Market Guides

• 1.1 Situation Analysis
• 1.2 Impact of Artificial Intelligence

2 Introduction and Market Definition

• 2.1 Market Definition
  • 2.1.1 Market Size
  • 2.1.2 Currency
  • 2.1.3 Years
• 2.2 Methodology
  • 2.2.1 Methodology
  • 2.2.2 Sources
  • 2.2.3 Authors
• 2.3 Perspective: Healthcare and the IVD Industry
  • 2.3.1 Global Healthcare Spending
  • 2.3.2 Spending on Diagnostics
  • 2.3.3 Important Role of Insurance for Diagnostics
• 2.4 The Nature of the IVD Product
  • 2.4.1 Features Overview
  • 2.4.2 The Misunderstood Feature
  • 2.4.3 Regulation
  • 2.4.4 The Newest Feature
  • 2.4.5 The Oldest Feature
  • 2.4.6 All About Scope
  • 2.4.7 Why Turnaround is Becoming More Important
  • 2.4.8 The Role of Trust
• 2.5 The IVD Product of the Future

3 Infectious Diseases - Guide to the Pathogens

• 3.1 Infectious Disease Pathogens - The Big Picture
  • 3.1.1 Viruses
  • 3.1.2 Bacteria
  • 3.1.3 Fungi
  • 3.1.4 Parasites
  • 3.1.5 Prions
  • 3.1.6 Virulence
  • 3.1.7 Transmission
• 3.2 The Coronavirus
  • 3.2.1 Severe acute respiratory syndrome (SARS)
  • 3.2.2 Middle East respiratory syndrome (MERS)
  • 3.2.3 COVID-19. The SARS CoV 2 Virus.
    • 3.2.3.1 Signs and symptoms
    • 3.2.3.2 Transmission
    • 3.2.3.3 Diagnosis
    • 3.2.3.4 Prevention
    • 3.2.3.5 Management
    • 3.2.3.6 Prognosis

4 Industry Overview

• 4.1 Players in a Dynamic Market
  • 4.1.1 Academic Research Lab
  • 4.1.2 Diagnostic Test Developer
  • 4.1.3 Instrumentation Supplier
  • 4.1.4 Chemical/Reagent Supplier
  • 4.1.5 Pathology Supplier
  • 4.1.6 Independent Clinical Laboratory
  • 4.1.7 Public National/regional Laboratory
  • 4.1.8 Hospital Laboratory
  • 4.1.9 Physicians Office Lab (POLS)
  • 4.1.10 Audit Body
  • 4.1.11 Certification Body
• 4.2 The Clinical Laboratory Market Segments
  • 4.2.1 Traditional Market Segmentation
  • 4.2.2 Laboratory Focus and Segmentation
  • 4.2.3 Segmenting the Syndromic Testing Market
• 4.3 Industry Structure
  • 4.3.1 Hospital Testing Share
  • 4.3.2 Economies of Scale
  • 4.3.3 Hospital vs. Central Lab
  • 4.3.4 Physician Office Lab's
  • 4.3.5 Physician's and POCT

5 Market Trends

• 5.1 Factors Driving Growth
  • 5.1.1 The Nucleic Acid Impact
  • 5.1.2 Population Dynamics
  • 5.1.3 The Developing World
  • 5.1.4 Decentralization
  • 5.1.5 Self Testing
  • 5.1.6 The Need for Speed
• 5.2 Factors Limiting Growth
  • 5.2.1 Costs and Experience Curve Effects
  • 5.2.2 The Role of ID Prevalence
  • 5.2.3 Wellness
  • 5.2.4 The Impact of Living Standards
• 5.3 Instrumentation, Automation and Diagnostic Trends
  • 5.3.1 Traditional Automation and Centralization
  • 5.3.2 The New Automation, Decentralization and Point Of Care
  • 5.3.3 Instruments Key to Market Share
  • 5.3.4 Bioinformatics Plays a Role
  • 5.3.5 PCR Takes Command
  • 5.3.6 Next Generation Sequencing Fuels a Revolution
  • 5.3.7 NGS Impact on Pricing
  • 5.3.8 Whole Genome Sequencing, A Brave New World
  • 5.3.9 Companion Diagnostics Blurs Diagnosis and Treatment

6 Clinical Laboratory MDx Infectious Disease Recent Developments

• 6.1 Recent Developments - Importance and How to Use This Section
  • 6.1.1 Importance of These Developments
  • 6.1.2 How to Use This Section
• 6.2 Presymptom Health Nabs Funding for Sepsis Test
• 6.3 FDA Clears BioMerieux GI Panel
• 6.4 Rapid Infection Diagnostic Launches BSIDx
• 6.5 Biotia's AI-, Sequencing-Based UTI Test approved
• 6.6 Delve Bio, Broad Clinical Labs Partner for Metagenomic
• 6.7 Roche Respiratory Panel Receives FDA EUA
• 6.8 Genetic Signatures Gets Approval for GI Parasite Panel
• 6.9 Diasorin Expands Respiratory Panel
• 6.10 BioMerieux Outlines MDx-Driven Growth
• 6.11 T2 Biosystems Gets Extended T2Bacteria Panel
• 6.12 Diasorin Aims to Deliver Updated Instruments, New Assays
• 6.13 Oxford Nanopore Nabs Investment From BioMerieux
• 6.14 Day Zero Diagnostics Closes Financing Round
• 6.15 Spindiag Seeks Investors for Rapid PCR System
• 6.16 Sorrento Therapeutics Nabs Contract for Dx Platform
• 6.17 Kephera Planning Menu of Infectious Disease Tests
• 6.18 Oxford Nanopore and BioMerieux to Develop IDDx
• 6.19 SD Biosensor Eyes Global Expansion
• 6.20 Selux Dx Next Gen Phenotyping Gets FDA Clearance
• 6.21 Takara Developing High-Throughput Multiplex Panels
• 6.22 BioGX Debuts New Point-of-Care Molecular Testing System
• 6.23 Nanopath MDx Platform Providing 15-Minute Results
• 6.24 ProtonDx Commercializing Rapid MDx Instrument
• 6.25 Hologic Obtains CE Mark for MDx Epstein-Barr, BK Virus Assays
• 6.26 Pathogenomix Infectious Disease Platform Uses Cloud-Based Analytics, NGS
• 6.27 Accelerate Diagnostics Anticipates Growth
• 6.28 Lumos Diagnostics Expanding Test Portfolio
• 6.29 Study Validates Karius Cell-Free DNA to Detect Hundreds of Pathogens

7 Key Companies

• 7.1 Abbott Laboratories
• 7.2 Agilent
• 7.3 Altona Diagnostics
• 7.4 Anitoa
• 7.5 Autonomous Medical Devices
• 7.6 Beckman Coulter Diagnostics (Danaher)
• 7.7 Becton, Dickinson and Company
• 7.8 BioGX
• 7.9 Biomatik
• 7.10 bioMerieux Diagnostics
• 7.11 Bio-Rad Laboratories, Inc
• 7.12 Cepheid (Danaher)
• 7.13 Diasorin S.p.A.
• 7.14 DNAe
• 7.15 Flow Health
• 7.16 Global Access Diagnostics
• 7.17 Great Basin Scientific, Inc
• 7.18 Hologic
• 7.19 Novacyt
• 7.20 Novus Diagnostics
• 7.21 Oncimmune
• 7.22 One Codex
• 7.23 OraSure Technologies
• 7.24 Prometheus Laboratories
• 7.25 Qiagen
• 7.26 QuidelOrtho
• 7.27 R-Biopharm AG
• 7.28 Response Biomedical
• 7.29 Revvity
• 7.30 Roche Diagnostics
• 7.31 Siemens Healthineers
• 7.32 Thermo Fisher Scientific
• 7.33 Vela Diagnostics
• 7.34 Veredus Laboratories
• 7.35 YD Diagnostics
• 7.36 Zhejiang Orient Gene Biotech

8 The Global Market for Clinical Laboratory MDx Infectious Disease

• 8.1 Global Market Overview by Country
  • 8.1.1 Table - Global Market by Country
  • 8.1.2 Chart - Global Market by Country
• 8.2 Global Market by Application - Overview
  • 8.2.1 Table - Global Market by Application
  • 8.2.2 Chart - Global Market by Application - Base/Final Year Comparison
  • 8.2.3 Chart - Global Market by Application - Base Year
  • 8.2.4 Chart - Global Market by Application - End Year
  • 8.2.5 Chart - Global Market by Application - Share by Year
  • 8.2.6 Chart - Global Market by Application - Segments Growth
• 8.3 Global Market by Place - Overview
  • 8.3.1 Table - Global Market by Place
  • 8.3.2 Chart - Global Market by Place - Base/Final Year Comparison
  • 8.3.3 Chart - Global Market by Place - Base Year
  • 8.3.4 Chart - Global Market by Place - End Year
  • 8.3.5 Chart - Global Market by Place - Share by Year
  • 8.3.6 Chart - Global Market by Place - Segments Growth

9 Global Clinical Laboratory MDx Infectious Disease Markets - By Application

• 9.1 Respiratory
  • 9.1.1 Table Respiratory - by Country
  • 9.1.2 Chart - Respiratory Growth
• 9.2 Blood Borne Virus
  • 9.2.1 Table Blood Borne Virus - by Country
  • 9.2.2 Chart - Blood Borne Virus Growth
• 9.3 Transplant
  • 9.3.1 Table Transplant - by Country
  • 9.3.2 Chart - Transplant Growth
• 9.4 Hospital Acquired Infections
  • 9.4.1 Table Hospital Acquired Infections - by Country
  • 9.4.2 Chart - Hospital Acquired Infections Growth
• 9.5 Reproductive Health
  • 9.5.1 Table Reproductive Health - by Country
  • 9.5.2 Chart - Reproductive Health Growth
• 9.6 C19 Singleplex
  • 9.6.1 Table C19 Singleplex - by Country
  • 9.6.2 Chart - C19 Singleplex Growth
• 9.7 Meningitis
  • 9.7.1 Table Meningitis - by Country
  • 9.7.2 Chart - Meningitis Growth
• 9.8 Gastrointestinal
  • 9.8.1 Table Gastrointestinal - by Country
  • 9.8.2 Chart - Gastrointestinal Growth
• 9.9 Tropical
  • 9.9.1 Table Tropical - by Country
  • 9.9.2 Chart - Tropical Growth

10 Global Clinical Laboratory MDx Infectious Disease Markets - By Place

• 10.1 Hospital Lab
  • 10.1.1 Table Hospital Lab - by Country
  • 10.1.2 Chart - Hospital Lab Growth
• 10.2 Outpatient Lab
  • 10.2.1 Table Outpatient Lab - by Country
  • 10.2.2 Chart - Outpatient Lab Growth
• 10.3 Point of Care
  • 10.3.1 Table Point of Care - by Country
  • 10.3.2 Chart - Point of Care Growth
• 10.4 Other Place
  • 10.4.1 Table Other Place - by Country
  • 10.4.2 Chart - Other Place Growth

11 Appendices

• 11.1 Growth of Approved IVD Test Menu
• 11.2 Growth of Approved Average IVD Test Fee
• 11.3 The Most Used IVD Assays
• 11.4 The Highest Grossing Assays
• 11.5 Laboratory Fees Schedule

Table of Tables

• Table 1 Key IVD Features
• Table 2 Features in the Future
• Table 3 Viral Pathogens and Families
• Table 4 Characteristics of Coronavirus Pandemic Infections
• Table 5 COVID-19 Symptoms
• Table 6 Market Players by Type
• Table 7 Clinical Laboratory Departments and Segments
• Table 8 Laboratory Management Focus - Different Approaches
• Table 9 Key Segmentation Variables Going Forward
• Table 10 Possible Market Segments of Syndromic Multiplex Market
• Table 11 Five Factors Driving Growth
• Table 12 Four Factors Limiting Growth
• Table 13 Seven Key Diagnostic Laboratory Technology Trends
• Table 14 - Global Market by Region
• Table 15 Global Market by Application
• Table 16 Global Market by Place
• Table 17 Respiratory by Country
• Table 18 Blood Borne Virus by Country
• Table 19 Transplant by Country
• Table 20 Hospital Acquired Infections by Country
• Table 21 Reproductive Health by Country
• Table 22 C19 Singleplex by Country
• Table 23 Meningitis by Country
• Table 24 Gastrointestinal by Country
• Table 25 Tropical by Country
• Table 26 Hospital Lab by Country
• Table 27 Outpatient Lab by Country
• Table 28 Point of Care by Country
• Table 29 Other Place by Country
• Table 30 The Most Common Assays
• Table 31 Largest Revenue Assays
• Table 32 Clinical Lab Fee Schedule

Table of Figures

• Figure 1 Global Health Care Spending Per Capita
• Figure 2 The Lab Test Pie
• Figure 3 Structure of a Typical Virus
• Figure 4 Mycobacterium Tuberculosis
• FIGURE 5 STRUCTURE OF CORONAVIRUSES
• Figure 6 The Road to Diagnostics
• Figure 7 The Changing Age of The World's Population
• Figure 8 Health Care Consumption by Age
• Figure 9 Cancer Incidence - Age at Diagnosis
• Figure 10 Percentage of World Population Over 65
• Figure 11 Chart Infectious Disease Decline
• Figure 12 Centralized vs. Decentralized Laboratory Service
• Figure 13 A Highly Multiplexed Syndromic Testing Unit
• Figure 14 The Real Cost to Sequence the Human Genome
• Figure 15 The Codevelopment Process
• Figure 16 Global Market Share Chart
• Figure 17 Global Market by Application - Base vs. Final
• Figure 18 Global Market by Application Base Year
• Figure 19 Global Market by Application End Year
• Figure 20 Application Share by Year
• Figure 21 Application Segments Growth
• Figure 22 Global Market by Place - Base vs. Final
• Figure 23 Global Market by Place Base Year
• Figure 24 Global Market by Place End Year
• Figure 25 Place Share by Year
• Figure 26 Place Segments Growth
• Figure 27 Respiratory Growth
• Figure 28 Blood Borne Virus Diagnostics Growth
• Figure 29 Transplant Growth
• Figure 30 Hospital Acquired Infections Growth
• Figure 31 Reproductive Health Growth
• Figure 32 C19 Singleplex Growth
• Figure 33 Meningitis Growth
• Figure 34 Gastrointestinal Growth
• Figure 35 Tropical Growth
• Figure 36 Hospital Lab Growth
• Figure 37 Outpatient Lab Growth
• Figure 38 Point of Care Growth
• Figure 39 Other Place Growth
• Figure 40 IVD Test Menu Growth
• Figure 41 IVD Test Average Fees - A Ten Year View